

## Editing the Genome to Treat Cardiovascular Disease

Joshua Knowles, MD PhD, Kevin M. Alexander, MD

### References

- AbouEzzeddine, O. F., Davies, D. R., Scott, C. G., Fayyaz, A. U., Askew, J. W., McKie, P. M., ... & Redfield, M. M. (2021). Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. *JAMA cardiology*, 6(11), 1267-1274.
- Abul-Husn, N. S., Manickam, K., Jones, L. K., Wright, E. A., Hartzel, D. N., Gonzaga-Jauregui, C., ... & Murray, M. F. (2016). Genetic identification of familial hypercholesterolemia within a single US health care system. *Science*, 354(6319), aaf7000.
- Adams, D., Gonzalez-Duarte, A., O'Riordan, W. D., Yang, C. C., Ueda, M., Kristen, A. V., ... & Suhr, O. B. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *New England Journal of Medicine*, 379(1), 11-21.
- Ando, Y., Adams, D., Benson, M. D., Berk, J. L., Planté-Bordeneuve, V., Coelho, T., ... & Merlini, G. (2022). Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. *Amyloid*, 29(3), 143-155.
- Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., ... & Coelho, T. (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. *New England Journal of Medicine*, 379(1), 22-31.
- Boucek, D., Jirikowic, J., & Taylor, M. (2011). Natural history of Danon disease. *Genetics in Medicine*, 13(6), 563-568.
- Brambatti, M., Caspi, O., Maolo, A., Koshi, E., Greenberg, B., Taylor, M. R., & Adler, E. D. (2019). Danon disease: Gender differences in presentation and outcomes. *International Journal of Cardiology*, 286, 92-98.
- Coelho, T., Marques, W., Dasgupta, N. R., Chao, C. C., Parman, Y., França, M. C., ... & NEURO-TTRransform Investigators. (2023). Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. *JAMA*, 330(15), 1448-1458.
- Cuchel, M., Bajaj, A., Carr, R., Sikora, T., Duell, P. B., Tardif, J. C., ... & Rader, D. J. (2020, April). Use of prophylactic steroids to mitigate potential T-cell response in AAV8-mediated hLDLR gene transfer in subjects with homozygous familial hypercholesterolemia. In *MOLECULAR THERAPY* (Vol. 28, No. 4, pp. 271-271). 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA: CELL PRESS.
- Castano, A., Narotsky, D. L., Hamid, N., Khalique, O. K., Morgenstern, R., DeLuca, A., ... & Maurer, M. S. (2017). Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *European heart journal*, 38(38), 2879-2887.
- Damy, T., Costes, B., Haggège, A. A., Donal, E., Eicher, J. C., Slama, M., ... & Buxbaum, J. N. (2016). Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. *European heart journal*, 37(23), 1826-1834.

- Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. *Nature*, 578(7794), 229-236.
- Falk, R. H., Alexander, K. M., Liao, R., & Dorbala, S. (2016). AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. *Journal of the American College of Cardiology*, 68(12), 1323-1341.
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., ... & Lebowitz, D. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. *New England Journal of Medicine*, 385(6), 493-502.
- González-López, E., Gallego-Delgado, M., Guzzo-Merello, G., de Haro-Del Moral, F. J., Cobo-Marcos, M., Robles, C., ... & Garcia-Pavia, P. (2015). Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. *European heart journal*, 36(38), 2585-2594.
- Hershberger, R. E., Hedges, D. J., & Morales, A. (2013). Dilated cardiomyopathy: the complexity of a diverse genetic architecture. *Nature reviews cardiology*, 10(9), 531-547.
- Corrado, D., Basso, C., & Judge, D. P. (2017). Arrhythmogenic cardiomyopathy. *Circulation research*, 121(7), 784-802.
- High, K. A., & Roncarolo, M. G. (2019). Gene Therapy. *The New England journal of medicine*, 381(5), 455–464. <https://doi.org/10.1056/NEJMra1706910>
- Kasiewicz, L. N., Biswas, S., Beach, A., Ren, H., Dutta, C., Mazzola, A. M., ... & Bellinger, A. M. (2023). GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. *Nature Communications*, 14(1), 2776.
- Lek, A., Wong, B., Keeler, A., Blackwood, M., Ma, K., Huang, S., ... & Flotte, T. (2023). Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy. *New England Journal of Medicine*, 389(13), 1203-1210.
- Longhi, S., Guidalotti, P. L., Quarta, C. C., Gagliardi, C., Milandri, A., Lorenzini, M., ... & Rapezzi, C. (2014). Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. *JACC: Cardiovascular Imaging*, 7(5), 531-532.
- Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & Gonzalez-Aseguinolaza, G. (2021). Novel vectors and approaches for gene therapy in liver diseases. *JHEP Reports*, 3(4), 100300.
- Manso, A. M., Hashem, S. I., Nelson, B. C., Gault, E., Soto-Hermida, A., Villarruel, E., ... & Adler, E. D. (2020). Systemic AAV9. LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease. *Science Translational Medicine*, 12(535), eaax1744.
- Marian, A. J., & Braunwald, E. (2017). Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circulation research*, 121(7), 749-770.
- Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., ... & Rapezzi, C. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *New England Journal of Medicine*, 379(11), 1007-1016.
- Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., ... & Gillmore, J. D. (2023). Patisiran treatment in patients with transthyretin cardiac amyloidosis. *New England Journal of Medicine*, 389(17), 1553-1565.

- Mlinaric, M., Bratanic, N., Dragos, V., Skarlovnik, A., Cevc, M., Battelino, T., & Groseelj, U. (2020). Case report: liver transplantation in homozygous familial hypercholesterolemia (HoFH)—long-term follow-up of a patient and literature review. *Frontiers in Pediatrics*, 8, 567895.
- Mohammed, S. F., Mirzoyev, S. A., Edwards, W. D., Dogan, A., Grogan, D. R., Dunlay, S. M., ... & Redfield, M. M. (2014). Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. *JACC: Heart Failure*, 2(2), 113-122.
- Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., ... & Kathiresan, S. (2021). In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. *Nature*, 593(7859), 429-434.
- Park, J., Levin, M. G., Haggerty, C. M., Hartzel, D. N., Judy, R., Kember, R. L., Reza, N., Regeneron Genetics Center, Ritchie, M. D., Owens, A. T., Damrauer, S. M., & Rader, D. J. (2020). A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. *Genetics in medicine : official journal of the American College of Medical Genetics*, 22(1), 102–111. <https://doi.org/10.1038/s41436-019-0625-8>
- Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., ... & Kastelein, J. J. (2020). Inclisiran for the treatment of heterozygous familial hypercholesterolemia. *New England Journal of Medicine*, 382(16), 1520-1530.
- Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S., Ali, S., ... & Gaudet, D. (2020). Evinacumab in patients with refractory hypercholesterolemia. *New England Journal of Medicine*, 383(24), 2307-2319.
- Rossano, J., Taylor, M., Lin, K., Epstein, S., Battiprolu, P., Ricks, D., ... & Greenberg, B. (2022). Phase 1 Danon Disease Results: The First Single Dose Intravenous (IV) Gene Therapy (RP-A501) With Recombinant Adeno-Associated Virus (AAV9: LAMP2B) for a Monogenic Cardiomyopathy. *Circulation*, 146(Suppl\_1), A11117-A11117.
- Rossano, J., Taylor, M., Lin, K., Epstein, S., Battiprolu, P., Ricks, D., ... & Greenberg, B. (2022). Phase 1 Danon Disease Results: The First Single Dose Intravenous (IV) Gene Therapy (RP-A501) With Recombinant Adeno-Associated Virus (AAV9: LAMP2B) for a Monogenic Cardiomyopathy. *Circulation*, 146(Suppl\_1), A11117-A11117.
- Schwartz, P. J., Stramba-Badiale, M., Crotti, L., Pedrazzini, M., Besana, A., Bosi, G., ... & Spazzolini, C. (2009). Prevalence of the congenital long-QT syndrome. *Circulation*, 120(18), 1761-1767.
- Tromp, T. R., Stroes, E. S., & Hovingh, G. K. (2020). Gene-based therapy in lipid management: the winding road from promise to practice. *Expert Opinion on Investigational Drugs*, 29(5), 483-493.
- Tirronen, A., Hokkanen, K., Vuorio, T., & Ylä-Herttuala, S. (2019). Recent advances in novel therapies for lipid disorders. *Human Molecular Genetics*, 28(R1), R49-R54.
- Watts, G. F., Schwabe, C., Scott, R., Gladding, P. A., Sullivan, D., Baker, J., ... & Ballantyne, C. M. (2023). RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. *Nature Medicine*, 29(9), 2216-2223.

